IB
IBT.LSE International Biotechnology Trust plc
- Market cap
- GBX 329M
- P/E
- 4.3x
- P/B
- 1.04x
- ROE
- 108.4%
- Dividend yield
- 3.03%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Feb 2026.
Is IBT.LSE undervalued?
Graham numberIBT.LSE trades 55.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
International Biotechnology Trust plc fundamental analysis
No fundamental analysis for International Biotechnology Trust plc yet.
International Biotechnology Trust plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About International Biotechnology Trust plc
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiol…
Full company profileInternational Biotechnology Trust plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Feb 28, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
International Biotechnology Trust plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | -6.06M | 46.4M | 21.1M | -16.6M | 54.6M | 29.1M | -21.1M | 8.49M | 42.3M | 18.7M | 352M |
| Gross Profit | -8.53M | 43.9M | 19.4M | -16.6M | 54.6M | 29.1M | -21.1M | 8.49M | 40.1M | 14.4M | 342M |
| Operating Income | -6.90M | 45.5M | 20.2M | -17.4M | 53.6M | 28.0M | -21.7M | 6.94M | 39.6M | -21.0K | 340M |
| EBITDA | -212K | 45.3M | 20.0M | -17.4M | 53.6M | 28.0M | -21.7M | 6.94M | 39.6M | -21.0K | 344M |
| Net Income | -7.22M | 45.3M | 20.0M | -17.5M | 53.4M | 27.9M | -22.5M | 6.81M | 38.9M | -1.17M | 342M |
| EPS | -0.19 | 1.21 | 0.53 | -0.46 | 1.39 | 0.69 | -0.55 | 0.17 | 1.02 | -0.03 | 11 |
| Balance Sheet | |||||||||||
| Total Assets | 231M | 272M | 263M | 241M | 303M | 348M | 327M | 305M | 308M | 284M | 347M |
| Total Liabilities | 14.5M | 19.7M | 744K | 42.0K | 18.8M | 24.1M | 42.0M | 34.6M | 25.9M | 34.6M | 32.0M |
| Shareholders' Equity | 217M | 253M | 262M | 240M | 284M | 324M | 285M | 270M | 282M | 249M | 315M |
| Cash & Short-term Investments | 90.0K | 128K | 142K | 886K | 324K | 1.56M | 0.00 | 0.00 | 10.4M | 15.0M | 2.97M |
| Total Debt | 11.8M | 6.39M | 374K | - | 18.1M | 21.9M | 40.0M | 32.5M | 22.8M | 29.6M | 29.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 21.5M | 14.7M | 16.2M | 6.47M | -9.55M | -14.5M | 1.12M | 27.3M | 45.4M | 28.6M | -15.7M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 45.4M | 28.6M | 0.00 |
| Free Cash Flow | 21.5M | 14.7M | 16.2M | 6.47M | -9.55M | -14.5M | 1.12M | 27.3M | 45.4M | 28.6M | -15.7M |
| Ratios | |||||||||||
| ROE | -3.3% | 17.9% | 7.6% | -7.3% | 18.8% | 8.6% | -7.9% | 2.5% | 13.8% | -0.5% | 108.4% |
| ROA | -3.1% | 16.6% | 7.6% | -7.3% | 17.6% | 8.0% | -6.9% | 2.2% | 12.6% | -0.4% | 98.4% |
| Net Profit Margin | - | 97.6% | 94.6% | - | 97.8% | 95.8% | - | 80.2% | 91.8% | -6.3% | 97.2% |
| Debt to Equity | 0.05x | 0.03x | 0.00x | - | 0.06x | 0.07x | 0.14x | 0.12x | 0.08x | 0.12x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
International Biotechnology Trust plc dividends
- Dividend yield
- 3.03%
- Forward dividend
- 0.31 GBX
- Payout ratio
- -
- Ex-dividend date
- Jul 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | GBP 11.2M | 0.32 | - |
| 2024 | GBP 10.8M | 0.28 | 27.7% |
| 2023 | GBP 11.4M | 0.28 | 167.4% |
| 2022 | GBP 12.9M | 0.31 | - |
| 2021 | GBP 11.6M | 0.29 | 41.5% |
| 2020 | GBP 9.55M | 0.25 | 17.9% |
| 2019 | GBP 10.6M | 0.28 | - |
| 2018 | GBP 10.1M | 0.27 | 50.8% |
| 2017 | GBP 8.64M | 0.23 | 19.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns International Biotechnology Trust plc
- Insiders 1.35%
- Institutions 22.85%
- Public & others 75.80%
- Shares outstanding 31.7M
- Free float 19.9M
International Biotechnology Trust plc company profile
- Company name
- International Biotechnology Trust plc
- Ticker
- IBT.LSE
- ISIN
- GB0004559349
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Capital Markets
- Fiscal year end
- August
- Address
- 31 Gresham Street, London, United Kingdom, EC2V 7QA
- Phone
- 44 20 7421 7070
- Website
- internationalbiotrust.com
About International Biotechnology Trust plc
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of the
International Biotechnology Trust plc management
3- Ms. Catherine Elizabeth Bingham M.B.A.Managing Partner · born 1967
- Ms. Claire JacksonCompany Secretary
- Dr. Carl Harald Janson and CEFA, M.D., Ph.D.Lead Investment Manager